Pehub -- ExonHit Therapeutics SA, a listed French therapeutics company, has agreed to acquire RedPath Integrated Pathology Inc., a Pittsburgh-based cancer diagnostics company. The deal is valued at upwards of $32 million, including up-front payments of $12.5 million in cash and $10 million in stock. RedPath had raised over $10 million in VC funding from Seneca Health Partners, Inflexion Partners, HMA Capital Partners New Spring Capital and CID Capital.
